GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Porton Pharma Solutions Ltd (SZSE:300363) » Definitions » Equity-to-Asset

Porton Pharma Solutions (SZSE:300363) Equity-to-Asset : 0.62 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Porton Pharma Solutions Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Porton Pharma Solutions's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥5,679 Mil. Porton Pharma Solutions's Total Assets for the quarter that ended in Mar. 2024 was ¥9,212 Mil. Therefore, Porton Pharma Solutions's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.62.

The historical rank and industry rank for Porton Pharma Solutions's Equity-to-Asset or its related term are showing as below:

SZSE:300363' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.44   Med: 0.6   Max: 0.78
Current: 0.62

During the past 13 years, the highest Equity to Asset Ratio of Porton Pharma Solutions was 0.78. The lowest was 0.44. And the median was 0.60.

SZSE:300363's Equity-to-Asset is ranked better than
56.99% of 1088 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs SZSE:300363: 0.62

Porton Pharma Solutions Equity-to-Asset Historical Data

The historical data trend for Porton Pharma Solutions's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Porton Pharma Solutions Equity-to-Asset Chart

Porton Pharma Solutions Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.78 0.74 0.61 0.59 0.62

Porton Pharma Solutions Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.63 0.62 0.66 0.62 0.62

Competitive Comparison of Porton Pharma Solutions's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Porton Pharma Solutions's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Porton Pharma Solutions's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Porton Pharma Solutions's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Porton Pharma Solutions's Equity-to-Asset falls into.



Porton Pharma Solutions Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Porton Pharma Solutions's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=5800.733/9384.029
=0.62

Porton Pharma Solutions's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=5678.949/9212.265
=0.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Porton Pharma Solutions  (SZSE:300363) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Porton Pharma Solutions Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Porton Pharma Solutions's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Porton Pharma Solutions (SZSE:300363) Business Description

Traded in Other Exchanges
N/A
Address
Fangzheng Avenue, Porton New Drug Outsourcing Service and R&D Center, Shuitu, Beibei District, Chongqing, CHN, 400714
Porton Pharma Solutions Ltd is a China-based external manufacturing supplier of custom drug intermediates and Active Pharmaceutical Ingredients (APIs) to pharmaceutical companies. It is engaged in the process development activities and pilot-scale and commercial-scale manufacturing activities.
Executives
Wang Zhong Neng Executives
Yu Yong Mei Executives
Sun Min Executives
Ji Yao Hui Executives
Ju Nian Feng Directors, executives
Tan Jun Supervisors
Xu Ai Wu Directors, executives
Guo Yong Qing Independent director
Director
Director
Ceng Hui Supervisors
Chen Bei Executives

Porton Pharma Solutions (SZSE:300363) Headlines

No Headlines